AK Medical Holdings Ltd. (1789) AI Stock Analysis

• Market Cap: HK$7.04B
• Dividend Yield: 0.74%
• Average Volume (3M): 3.05M
• Price to Earnings (P/E): 23.6
• Beta (1Y): 1.21
• Revenue Growth: 20.19%
• EPS Growth: 45.54%
• Country: HK
• Employees: 950
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): 0.27
• Shares Outstanding: 1,122,695,800
• 10 Day Avg. Volume: 3,226,783
• 30 Day Avg. Volume: 3,046,725
• PEG Ratio: 0.50
• Price to Book (P/B): 2.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 371.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$5.50
• Price Target Upside: -9.69% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: ―

AK Medical Holdings Ltd. demonstrates strong financial health with robust revenue growth and effective cost management. The technical analysis supports a positive stock momentum. However, challenges in cash flow management and a moderate valuation slightly offset these strengths.

AK Medical Holdings Ltd. Business Overview & Revenue Model

Company Description

AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products under the AK Medical brand in China and internationally. It offers knee, hip, and spine replacement implants; and 3D-printed products, such as 3D-printed hip replacement implants, 3D-printed artificial vertebral bodies, and 3D-printed spinal interbody cages. The company also distributes third party orthopedic products; and manufactures surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients. The company was founded in 2003 and is headquartered in Beijing, the People's Republic of China. AK Medical Holdings Limited is a subsidiary of Ximalaya Limited.

How the Company Makes Money

AK Medical Holdings Ltd. generates revenue primarily through the sale of its orthopedic products, including joint prostheses and surgical instruments, to hospitals, clinics, and healthcare providers. The company's revenue streams are bolstered by its strong emphasis on innovation and the use of advanced technologies such as 3D printing, which allows for the creation of highly customized implants tailored to individual patient needs. Additionally, AK Medical may engage in strategic partnerships and collaborations with healthcare institutions and research organizations to expand its market reach and enhance its product offerings. These partnerships can provide additional revenue opportunities through joint development projects and shared resources.

AK Medical Holdings Ltd. Financial Statement Overview

Summary

AK Medical Holdings Ltd. displays a strong financial position with impressive revenue growth and profitability metrics. The balance sheet is solid, with low leverage and high equity, ensuring financial stability. However, cash flow management poses some risks, requiring attention to improve consistency and support growth initiatives.

Income Statement

AK Medical Holdings Ltd. has demonstrated strong revenue growth over the years, with a significant increase from 2023 to 2024. The gross profit margin has remained healthy, with a slight improvement. Net profit margin has also seen an upward trend, indicating efficient cost management. EBIT and EBITDA margins are stable, showcasing effective operational management.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio, indicating low financial leverage. A high equity ratio reflects strong capitalization. The return on equity is solid, showcasing effective use of shareholder funds. Overall, the company is financially stable with a strong equity base and manageable liabilities.

Cash Flow

Cash flow from operations has been inconsistent, with a significant drop in the latest year. The free cash flow has also been volatile, reflecting potential challenges in managing capital expenditures and investments. However, the company's ability to generate operating cash flow relative to net income indicates potential for improvement.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.35B	1.09B	1.05B	761.44M	1.04B
	Gross Profit
808.19M	674.49M	636.43M	499.19M	714.53M
	EBIT
300.78M	211.48M	219.98M	99.44M	368.93M
	EBITDA
371.66M	323.34M	322.87M	184.33M	438.41M
	Net Income Common Stockholders
273.93M	182.10M	204.77M	92.62M	314.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.05B	726.67M	1.04B	841.13M	901.49M
	Total Assets
3.34B	3.00B	2.77B	2.61B	2.53B
	Total Debt
99.39M	84.20M	38.78M	41.56M	26.85M
	Net Debt
-252.78M	-247.01M	-587.05M	-434.05M	-686.24M
	Total Liabilities
697.21M	611.12M	530.73M	573.73M	484.13M
	Stockholders Equity
2.64B	2.39B	2.24B	2.03B	2.04B
Cash Flow		Free Cash Flow
0.00	-162.14M	121.20M	100.39M	115.47M
	Operating Cash Flow
0.00	33.94M	242.92M	176.62M	205.26M
	Investing Cash Flow
0.00	-318.15M	-82.29M	-297.10M	-356.41M
	Financing Cash Flow
0.00	-14.02M	-36.80M	-100.70M	611.74M

AK Medical Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1789, the sentiment is Positive. The current price of 6.09 is above the 20-day moving average (MA) of 5.81, above the 50-day MA of 5.83, and above the 200-day MA of 5.02, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 64.14 is Neutral, neither overbought nor oversold. The STOCH value of 92.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1789.

AK Medical Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	78 Outperform	HK$7.04B	23.59	10.92%	0.74%	20.19%	45.54%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
GNNSF		$4.64B	0.93	-6.09%	―	―	―
SFOSF		$8.87B	12.84	6.22%	1.96%	―	―
SHWGF		$3.30B	11.48	8.95%	3.60%	―	―
1336	75 Outperform	HK$158.35B	3.92	26.08%	4.25%	-43.77%	―
2199	56 Neutral	HK$1.90B	18.26	3.10%	3.03%	9.38%	-41.33%

AK Medical Holdings Ltd. Corporate Events

AK Medical Holdings Announces 2025 AGM and Key Resolutions

AK Medical Holdings Ltd. has announced its upcoming annual general meeting, scheduled for June 18, 2025, in Beijing, China. Key agenda items include the approval of financial statements, declaration of a final dividend, re-election of directors, and the reappointment of KPMG as auditors. Additionally, the company seeks shareholder approval for mandates to repurchase shares and issue additional shares, which could impact its market operations and shareholder value.

AK Medical Holdings Reports Strong Financial Growth in 2024

AK Medical Holdings Ltd. reported a substantial increase in its financial performance for the year ended December 31, 2024, with revenue rising by 23.1% and net profit increasing by 50.4% compared to the previous year. This growth is attributed to heightened demand for surgical products driven by the volume-based procurement policy and successful market expansion efforts, including increased overseas surgeries. The company has also recommended a final dividend payment of HK$7.2 cents per share, reflecting its robust financial health and commitment to shareholder returns.

AK Medical Holdings Declares Final Dividend for 2024

AK Medical Holdings Ltd. has announced a final cash dividend of HKD 0.072 per share for the financial year ending December 31, 2024. This decision reflects the company’s ongoing commitment to delivering shareholder value and may influence investor sentiment positively. The dividend will be paid on July 18, 2025, following shareholder approval on June 18, 2025. The announcement underscores the company’s stable financial performance and its strategic focus on maintaining a strong market position.

AK Medical Holdings Ltd. Schedules Board Meeting to Approve Annual Results

AK Medical Holdings Ltd. has announced that its board of directors will meet on March 26, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. The meeting will also discuss the recommendation of a final dividend and address other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

AK Medical Projects Over 50% Profit Increase for 2024

AK Medical Holdings Ltd. has issued a positive profit alert, anticipating a significant increase in net profit attributable to shareholders by over 50% for the year ended December 31, 2024, compared to the previous year. This expected growth is attributed to heightened demand for its surgical products and effective cost control measures, amidst stable operational costs and administrative expenses. Stakeholders are advised to interpret this preliminary assessment with caution, as the final audited results will be available by March 2025.